

Express Mail No. EV333999132US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	AGYT-006
	First Named Inventor	MUELLER, SABINE
	Application Number	09 983,000
	Confirmation No.	7766
	Filing Date	October 17, 2001
	Group Art Unit	1642
	Examiner Name	YU, MISOOK
Title: "USE OF PROTEIN BIOMOLECULAR TARGETS IN THE TREATMENT AND VISUALIZATION OF BRAIN TUMORS"		

RECEIVED

SEP 26 2003

TECH CENTER 1600/2900

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. AGYT-006 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: September 17, 2003

By:


Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/983,000
				Filing Date	October 17, 2001
				First Named Inventor	MUELLER, SABINE
				Art Unit	1642
				Examiner Name	YU, MISOOK
Sheet	1	of	2	Attorney Docket Number	AGYT-006

RECEIVED
SEP 26 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^h
		Country Code ² -Number ⁴ -Kind Code ³ (if known)				

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	✓	Huang H. et al., Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res., 2000, Vol 60, No 24, pp 6868-74	
		Huang YQ. et al., Identification of a family of alternatively spliced mRNA species of angiopoietin-1. Blood, 2000, Vol 95, No 6, pp 1993-9	
	✓	Tangumaran S. et al., Signal transduction via CD44: role of plasma membrane microdomains. Leuk Lymphoma, 1999, Vol 35, No 5-6, pp 455-69	
		Jaworski DM. et al., Intracranial injury acutely induces the expression of the secreted isoform of the CNS-specific hyaluronan-binding protein BEHAB/brevican. Exp Neurol, 1999, Vol 157, pp 327-37	
		Jin KL. et al., Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A, 2000, Vol 97, No 18, pp 10242-7	
	✓	Kim I. et al., Molecular cloning, expression, and characterization of angiopoietin-related protein: angiopoietin-related protein induces endothelial cell sprouting. J Biol Chem, 1999, Vol 274, No 37, pp 26523-8	
	✓	Kobayashi T. et al., The tetraspanin CD63/lamp3 cycles between endocytic and secretory compartments in human endothelial cells. Mol Biol Cell, 2000, Vol 11, No 5, pp 1829-43	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant 1 Applicant's unique citation designation number (optional) 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible 6 Applicant is to place a check mark here if English language Translation is attached

* Information on §§ 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to

Substitute for form 1449B/PTO			Complete if Known		
			Application Number	09/983,000	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	October 17, 2001	
			First Named Inventor	MUELLER, SABINE	
			Group Art Unit	1642	
			Examiner Name	YU, MISOOK	
Sheet	2	of	2	Attorney Docket Number	AGYT-006

RECEIVED

SEP 26 2003

TECH CENTER 1600/2900

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Koochekpour S, et al. Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Int J Cancer. 1995, Vol. 63, No. 3, pp 450-4	
		Lai A, et al. A public database for gene expression in human cancers. Cancer Res. 1999, Vol. 59, No. 21, pp 5403-7	
		Lamszus K, et al. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci. 1999, Vol. 17, No. 5-6, pp 517-30	
		Lee CC, Yamada KM. Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site. J Biol Chem. 1994, Vol. 269, No. 30, pp 19457-61	
		Lokker NA, et al. Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor. Protein Eng. 1994, Vol. 7, No. 7, pp 895-903	
		Lutz EM, et al. Domains determining agonist selectivity in chimeric VIP2 (VPAC2)/PACAP (PAC1) receptors. Br J Pharmacol. 1999, Vol. 128 No 4, pp 934-40	
		Maecker HT, et al. The tetraspanin superfamily: molecular facilitators. FASEB J. 1997, Vol. 11, No. 6, pp 428-42	
		Mark MR, et al. Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding. J Biol Chem. 1992, Vol. 267, No. 36, pp 26166-71	
		Matthews RT, et al. Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J Biol Chem. 2000, Vol. 275, No. 30, pp 22695-703	
		Monaghan M, et al. Epidermal growth factor up-regulates CD44-dependent astrocytoma invasion in vitro. J Pathol. 2000, Vol. 192, No. 4, pp 519-25	
		Moriyama T, et al. Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells. Clin Exp Metastasis. 1999, Vol. 17, No. 10, pp 873-9	
		Nagasaka S, et al. Alternative RNA splicing of the hyaluronic acid receptor CD44 in the normal human brain and in brain tumors. J Neurosurg. 1995, Vol. 82, No. 5, pp 858-63	
		Naldini L, et al. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol. 1991, Vol. 11, No 4, pp 1793-303	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes.

Please type a plus sign (+) inside this box .

PTO SB 21 (05-03)

Approved for use through 04/30/2003 OMB 0651-0031


U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing) Total Number of Pages in This Submission 4 + refs.	Application Number	09/983,000
	Filing Date	October 17, 2001
	First Named Inventor	MUELLER, SABINE
	Group Art Unit	1642
	Examiner Name	YU, MISOOK
	Attorney Docket Number	AGYT-006

RECEIVED
SEP 26 2003
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1 Form PTO/SB/08A 2 Copies of cited references 3 Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Signing Attorney, Agent (Reg. No.):	PAMELA J. SHERWOOD, 36,677 BOZICEVIC, FIELD & FRANCIS LLP
Signature:	
Date:	September 17, 2003

EXPRESS MAIL LABEL NO. EV333999132US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is restricted to 12 months to complete, including